Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase I/II clinical trial (SYS6055-003) of the SYS6055 injection developed by the Group to treat relapsed/refractory B-cell non-Hodgkin lymphoma has been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.